European Research Council

Company

Related News

PROTAC Technology Advances Toward Phase III Trials in Cancer Treatment

Proteolysis-targeting chimeras (PROTACs) are advancing from experimental to clinical-stage cancer therapies, with first candidates entering Phase III trials. The technology degrades target proteins rather than blocking them, offering new options for previously undruggable targets.

Related Clinical Trials

NCT ID Title Status Phase
NCT07108049

Strengthening Relationships and Mental Health Through a Couples-Based Economic Empowerment Intervention

RECRUITING NA
NCT06993415

Optimize Risk Prediction After Myocardial Infarction: The ORACLE Study

RECRUITING
NCT06960226

Replication Study: Reducing Pain With Focused Music Listening

COMPLETED NA
NCT06841692

Diuretic Testing in Chronic Kidney Disease

RECRUITING NA
NCT06793839

3D Contrast Enhanced Acoustic Perfusion Imaging in Adult After Subarachnoid Hemorrhage

RECRUITING NA
NCT06205160

Evaluation of New Flexible High-density Intra-operative ECoG Electrodes for Epilepsy Surgery. ( EpiGrid )

RECRUITING NA
NCT06121206

Effects of Altitude-like Cognition Training on Neuroplasticity and Cognitive Functions

COMPLETED NA
NCT06068322

Supramaximal High-Intensity Interval Training in People With and Without Chronic Obstructive Pulmonary Disease

RECRUITING NA
NCT05818345

Pricing Interventions Based on Energy Content in Restaurants

TERMINATED NA
NCT05698862

Mapping the Impact of Gut Microbiota on Brain and Behavior Through the Lens of GABA

RECRUITING NA